1
|
Qiu Z, Huang R, Wu Y, Li X, Sun C, Ma Y. Decoding the Structural Diversity: A New Horizon in Antimicrobial Prospecting and Mechanistic Investigation. Microb Drug Resist 2024; 30:254-272. [PMID: 38648550 DOI: 10.1089/mdr.2023.0232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024] Open
Abstract
The escalating crisis of antimicrobial resistance (AMR) underscores the urgent need for novel antimicrobials. One promising strategy is the exploration of structural diversity, as diverse structures can lead to diverse biological activities and mechanisms of action. This review delves into the role of structural diversity in antimicrobial discovery, highlighting its influence on factors such as target selectivity, binding affinity, pharmacokinetic properties, and the ability to overcome resistance mechanisms. We discuss various approaches for exploring structural diversity, including combinatorial chemistry, diversity-oriented synthesis, and natural product screening, and provide an overview of the common mechanisms of action of antimicrobials. We also describe techniques for investigating these mechanisms, such as genomics, proteomics, and structural biology. Despite significant progress, several challenges remain, including the synthesis of diverse compound libraries, the identification of active compounds, the elucidation of complex mechanisms of action, the emergence of AMR, and the translation of laboratory discoveries to clinical applications. However, emerging trends and technologies, such as artificial intelligence, high-throughput screening, next-generation sequencing, and open-source drug discovery, offer new avenues to overcome these challenges. Looking ahead, we envisage an exciting future for structural diversity-oriented antimicrobial discovery, with opportunities for expanding the chemical space, harnessing the power of nature, deepening our understanding of mechanisms of action, and moving toward personalized medicine and collaborative drug discovery. As we face the continued challenge of AMR, the exploration of structural diversity will be crucial in our search for new and effective antimicrobials.
Collapse
Affiliation(s)
- Ziying Qiu
- School of Pharmacy, Binzhou Medical University, Yantai, China
| | - Rongkun Huang
- School of Pharmacy, Binzhou Medical University, Yantai, China
| | - Yuxuan Wu
- School of Pharmacy, Binzhou Medical University, Yantai, China
| | - Xinghao Li
- School of Pharmacy, Binzhou Medical University, Yantai, China
| | - Chunyu Sun
- School of Pharmacy, Binzhou Medical University, Yantai, China
| | - Yunqi Ma
- School of Pharmacy, Binzhou Medical University, Yantai, China
| |
Collapse
|
2
|
Bispat AS, Cardoso FC, Hasan MM, Dongol Y, Wilcox R, Lewis RJ, Duggan PJ, Tuck KL. Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues. RSC Med Chem 2024; 15:916-936. [PMID: 38516585 PMCID: PMC10953480 DOI: 10.1039/d3md00714f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Accepted: 01/26/2024] [Indexed: 03/23/2024] Open
Abstract
Building on previous investigations, structural modifications to the neuronal calcium ion channel blocker MONIRO-1 and related compounds were conducted that included replacement of the amide linker with an aniline and isosteric sulfonamide moiety, and the previously used strategy of substitution of the guanidinium group with less hydrophilic amine functionalities. A comprehensive SAR study revealed a number of phenoxyaniline and sulfonamide compounds that were more potent or had similar potency for the CaV2.2 and CaV3.2 channel compared to MONIRO-1 when evaluated in a FLIPR-based intracellular calcium response assay. Cytotoxicity investigations indicated that the sulfonamide analogues were well tolerated by Cos-7 cells at dosages required to inhibit both calcium ion channels. The sulfonamide derivatives were the most promising CaV2.2 inhibitors developed by us to date due, possessing high stability in plasma, low toxicity (estimated therapeutic index > 10), favourable CNS MPO scores (4.0-4.4) and high potency and selectivity, thereby, making this class of compounds suitable candidates for future in vivo studies.
Collapse
Affiliation(s)
- Anjie S Bispat
- School of Chemistry, Monash University Victoria 3800 Australia
- CSIRO Manufacturing, Research Way Clayton Victoria 3168 Australia
| | - Fernanda C Cardoso
- Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia
| | - Md Mahadhi Hasan
- Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia
| | - Yashad Dongol
- Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia
| | - Ricki Wilcox
- School of Chemistry, Monash University Victoria 3800 Australia
| | - Richard J Lewis
- Institute for Molecular Bioscience, The University of Queensland St Lucia QLD 4072 Australia
| | - Peter J Duggan
- CSIRO Manufacturing, Research Way Clayton Victoria 3168 Australia
- College of Science and Engineering, Flinders University Adelaide South Australia 5042 Australia
| | - Kellie L Tuck
- School of Chemistry, Monash University Victoria 3800 Australia
| |
Collapse
|
3
|
Gonçalves Â, Matias M, Salvador JAR, Silvestre S. Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use? Int J Mol Sci 2024; 25:1600. [PMID: 38338879 PMCID: PMC10855265 DOI: 10.3390/ijms25031600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 01/22/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open
Abstract
Bismuth compounds are considered relatively non-toxic, with their low solubility in aqueous solutions (e.g., biological fluids) being the major contributing factor to this property. Bismuth derivatives are widely used for the treatment of peptic ulcers, functional dyspepsia, and chronic gastritis. Moreover, the properties of bismuth compounds have also been extensively explored in two main fields of action: antimicrobial and anticancer. Despite the clinical interest of bismuth-based drugs, several side effects have also been reported. In fact, excessive acute ingestion of bismuth, or abuse for an extended period of time, can lead to toxicity. However, evidence has demonstrated that the discontinuation of these compounds usually reverses their toxic effects. Notwithstanding, the continuously growing use of bismuth products suggests that it is indeed part of our environment and our daily lives, which urges a more in-depth review and investigation into its possible undesired activities. Therefore, this review aims to update the pharmaco-toxicological properties of bismuth compounds. A special focus will be given to in vitro, in vivo, and clinical studies exploring their toxicity.
Collapse
Affiliation(s)
- Ângela Gonçalves
- CICS-UBI—Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal; (Â.G.); (M.M.)
| | - Mariana Matias
- CICS-UBI—Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal; (Â.G.); (M.M.)
| | - Jorge A. R. Salvador
- Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal;
- CNC—Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
| | - Samuel Silvestre
- CICS-UBI—Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6201-506 Covilhã, Portugal; (Â.G.); (M.M.)
- CNC—Centre for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
| |
Collapse
|
4
|
Rosário JDS, Moreira FH, Rosa LHF, Guerra W, Silva-Caldeira PP. Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome. Molecules 2023; 28:5921. [PMID: 37570891 PMCID: PMC10421188 DOI: 10.3390/molecules28155921] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2023] [Revised: 08/04/2023] [Accepted: 08/05/2023] [Indexed: 08/13/2023] Open
Abstract
Bismuth-based drugs have been used primarily to treat ulcers caused by Helicobacter pylori and other gastrointestinal ailments. Combined with antibiotics, these drugs also possess synergistic activity, making them ideal for multiple therapy regimens and overcoming bacterial resistance. Compounds based on bismuth have a low cost, are safe for human use, and some of them are also effective against tumoral cells, leishmaniasis, fungi, and viruses. However, these compounds have limited bioavailability in physiological environments. As a result, there is a growing interest in developing new bismuth compounds and approaches to overcome this challenge. Considering the beneficial properties of bismuth and the importance of discovering new drugs, this review focused on the last decade's updates involving bismuth compounds, especially those with potent activity and low toxicity, desirable characteristics for developing new drugs. In addition, bismuth-based compounds with dual activity were also highlighted, as well as their modes of action and structure-activity relationship, among other relevant discoveries. In this way, we hope this review provides a fertile ground for rationalizing new bismuth-based drugs.
Collapse
Affiliation(s)
- Jânia dos Santos Rosário
- Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil
| | - Fábio Henrique Moreira
- Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil
| | - Lara Hewilin Fernandes Rosa
- Institute of Chemistry, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia 38400-142, MG, Brazil
| | - Wendell Guerra
- Institute of Chemistry, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia 38400-142, MG, Brazil
| | | |
Collapse
|
5
|
Medicinal bismuth: Bismuth-organic frameworks as pharmaceutically privileged compounds. Tetrahedron 2022. [DOI: 10.1016/j.tet.2022.133117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
6
|
Gómez-Oliveira EP, Méndez N, Iglesias M, Gutiérrez-Puebla E, Aguirre-Díaz LM, Monge MÁ. Building a Green, Robust, and Efficient Bi-MOF Heterogeneous Catalyst for the Strecker Reaction of Ketones. Inorg Chem 2022; 61:7523-7529. [PMID: 35510809 PMCID: PMC9115759 DOI: 10.1021/acs.inorgchem.2c00628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
In this work, we
present the new [Bi14(μ3-O)9(μ4-O)2(μ3–OH)5(3,5-DSB)5(H2O)3]·7H2O, BiPF-4 (bismuth
polymeric framework—4) MOF, its microwave hydrothermal synthesis,
as well as its behavior as a heterogeneous catalyst in the multicomponent
organic Strecker reaction. The BiPF-4 material shows
a three-dimensional (3D) framework formed by peculiar inorganic oxo-hydroxo-bismutate
layers connected among them through the 3,5-dsb (3,5-disulfobenzoic
acid) linker. These two-dimensional (2D) layers, built by junctions
of Bi7 polyhedra SBU, provide the material of many Lewis acid catalytic
sites because of the mixing in the metal coordination number. BiPF-4 is a highly robust, green, and stable material that
demonstrates an excellent heterogeneous catalytic activity in the
multicomponent Strecker reaction of ketones carried out in one-pot
synthesis, bringing a reliable platform of novel green materials based
on nontoxic and abundant metal sources such as bismuth. In this work, we present the new [Bi14(μ3-O)9(μ4-O)2(μ3−OH)5(3,5-DSB)5(H2O)3]·7H2O, BiPF-4 (bismuth
polymeric framework—4) MOF, its microwave hydrothermal synthesis,
as well as its behavior as a heterogeneous catalyst in the multicomponent
organic Strecker reaction.
Collapse
Affiliation(s)
- Eloy P Gómez-Oliveira
- Departamento de Nuevas Arquitecturas en Química de Materiales, Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas, Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid 28049, Spain
| | - Nayara Méndez
- Departamento de Nuevas Arquitecturas en Química de Materiales, Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas, Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid 28049, Spain
| | - Marta Iglesias
- Departamento de Nuevas Arquitecturas en Química de Materiales, Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas, Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid 28049, Spain
| | - Enrique Gutiérrez-Puebla
- Departamento de Nuevas Arquitecturas en Química de Materiales, Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas, Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid 28049, Spain
| | - Lina M Aguirre-Díaz
- Departamento de Nuevas Arquitecturas en Química de Materiales, Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas, Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid 28049, Spain
| | - M Ángeles Monge
- Departamento de Nuevas Arquitecturas en Química de Materiales, Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Científicas, Sor Juana Inés de la Cruz 3, Cantoblanco, Madrid 28049, Spain
| |
Collapse
|
7
|
Herdman M, Werrett MV, Andrews PC. Aryl bismuth phosphinates [BiAr2(O(O)PRR’)]: structure-activity relationships for antibacterial activity and cytotoxicity. Dalton Trans 2022; 51:9323-9335. [DOI: 10.1039/d2dt00346e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
To study and evaluate the structure-activity relationships in di-aryl bismuth phosphinates on antibacterial activity and cytotoxicity a series of complexes containing ortho-methoxyphenyl, meta-methoxyphenyl, meta-tolyl and para-tolyl aryl groups; [Bi(o-MeOPh)2(O(O)P(H)Ph)]n 1,...
Collapse
|
8
|
Griffith DM, Li H, Werrett MV, Andrews PC, Sun H. Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles. Chem Soc Rev 2021; 50:12037-12069. [PMID: 34533144 DOI: 10.1039/d0cs00031k] [Citation(s) in RCA: 64] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Bismuth as a relatively non-toxic and inexpensive metal with exceptional properties has numerous biomedical applications. Bismuth-based compounds are used extensively as medicines for the treatment of gastrointestinal disorders including dyspepsia, gastric ulcers and H. pylori infections. Recently, its medicinal application was further extended to potential treatments of viral infection, multidrug resistant microbial infections, cancer and also imaging, drug delivery and biosensing. In this review we have highlighted the unique chemistry and biological chemistry of bismuth-209 as a prelude to sections covering the unique antibacterial activity of bismuth including a description of research undertaken to date to elucidate key molecular mechanisms of action against H. pylori, the development of novel compounds to treat infection from microbes beyond H. pylori and the significant role bismuth compounds can play as resistance breakers. Furthermore we have provided an account of the potential therapeutic application of bismuth-213 in targeted alpha therapy as well as a summary of the biomedical applications of bismuth-based nanoparticles and composites. Ultimately this review aims to provide the state of the art, highlight the untapped biomedical potential of bismuth and encourage original contributions to this exciting and important field.
Collapse
Affiliation(s)
- Darren M Griffith
- Department of Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Ireland.,SSPC, Synthesis and Solid State Pharmaceutical Centre, Ireland
| | - Hongyan Li
- Department of Chemistry and CAS-HKU Joint Laboratory of Metallomics for Health and Environment, The University of Hong Kong, Pokfulam Road, Hong Kong, China.
| | | | - Philip C Andrews
- School of Chemistry, Monash University, Melbourne, VIC, Australia
| | - Hongzhe Sun
- Department of Chemistry and CAS-HKU Joint Laboratory of Metallomics for Health and Environment, The University of Hong Kong, Pokfulam Road, Hong Kong, China.
| |
Collapse
|
9
|
Małecka M, Skoczyńska A, Goodman DM, Hartinger CG, Budzisz E. Biological properties of ruthenium(II)/(III) complexes with flavonoids as ligands. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.213849] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
10
|
Senevirathna DC, Duffin RN, Stephens LJ, Herdman ME, Werrett MV, Andrews PC. Bismuth(III) Thiophosphinates: Understanding How a Small Atomic Change Influences Antibacterial Activity and Mammalian Cell Viability. Aust J Chem 2020. [DOI: 10.1071/ch20169] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Diphenylphosphinothioic acid (HSP(=O)Ph2) and diphenylphosphinodithioic acid (HSP(=S)Ph2) have been used to synthesise four BiIII complexes: 1 [Bi(SP(=O)Ph2)3], 2 [BiPh(SP(=O)Ph2)2], 3 [BiPh2(SP(=O)Ph2)], and 4 [Bi(SP(=S)Ph2)3], using BiPh3 and [Bi(OtBu)3] as bismuth sources. The complexes have been characterised by NMR spectroscopy, mass spectrometry, infrared spectroscopy, powder X-ray diffraction, and singe crystal X-ray crystallography (2–4). Biological studies indicated that despite complexes 2 and 3 reducing mammalian cell viability, their antibacterial activity provides a good degree of selectivity towards both Gram positive and Gram negative bacterial strains. The minimum inhibitory concentrations for complexes 2 and 3 are in the range of 0.52–5.5µM towards the bacteria tested. Homoleptic complexes 1 and 4 were generally less active towards both bacterial and mammalian cells.
Collapse
|